Search PubMed⌕ Search

Biomedical subjects

Paul Abrams

Publications and source records attributed to Paul Abrams.

At least 55 records · Page 3Linked to original sources
PubMed2004

Natural history of detrusor contractility--minimum ten-year urodynamic follow-up in men with bladder outlet obstruction and those with detrusor.

OBJECTIVE: To check the long-term effect, in male patients, of treated and untreated bladder outlet obstruction (BOO) on detrusor contractility and to explore the relationship between ageing and detrusor underactivity (DUA). MATERIAL AND METHODS: Men investigated at the urodynamic department of Southmead Hospital in Bristol between 1972 and 1986 were traced and three groups were invited for repeat pressure-flow urodynamic studies (PFS). The first two groups included patients over 40 years old, with untreated or surgically treated BOO, and the third group had patients with DUA from all age groups. RESULTS: 196 patients (with a minimum 10 year gap from the first assessment) agreed to have repeat PFS. There was no statistically significant change in bladder contractility index (BCI) in patients with BOO treated by transurethral resection of the prostate (TURP) (mean difference in BCI was 0.01, 95% confidence interval -0.07 to 0.09, n=114). There was also no significant difference in BCI in untreated patients with BOO (p=0.10, n=53). The follow-up BCI was higher in untreated patients than in the surgically treated group. The BCI in patients with DUA did not change significantly after a minimum of 10 years' follow-up. CONCLUSIONS: There is no evidence to suggest that detrusor contractility declines with long-term BOO. Relieving the obstruction surgically does not improve the contractility. This is important when considering and counselling for TURP. Underactive detrusors remain underactive, but do not get worse with time, which could indicate that this is not an ageing process per se and may even have a congenital basis.

Adult↗
PubMed2004

Noninvasive techniques for the measurement of isovolumetric bladder pressure.

PURPOSE: A total of 184,000 prostatectomies were performed in the United States in 2000 for the relief of presumed bladder outlet obstruction. However, it has been reported that prostatectomy using current indications fails to bring about symptomatic improvement in approximately one-fourth of patients. Pressure flow studies are currently recognized as the gold standard for the diagnosis of bladder outlet obstruction. However, these studies are associated with a number of disadvantages. They are time consuming, invasive and expensive, and carry some morbidity for the patient. It has been suggested that the use of pressure flow studies should be mandatory before surgery. The invasive nature of this test limits its application, and a variety of noninvasive methods have been suggested to circumvent the need for conventional urodynamics. MATERIALS AND METHODS: We conducted a MEDLINE search of the published literature on the use of noninvasive techniques to measure bladder pressure. RESULTS: Two promising techniques involve the noninvasive measurement of isovolumetric detrusor pressure. The first of these methods uses an external condom catheter and the second an inflatable cuff around the penis. Both of these methods rely on the interruption of urinary flow and the measurement of the bladder pressure transmitted along the fluid column between bladder and site of urethral occlusion. An alternative strategy analyzes flow patterns following compression and release of the urethra during voiding. CONCLUSIONS: Of the methods reported the penile cuff, which is inflated during voiding, or the penile squeeze technique, which infers bladder pressure from flow patterns, would seem the most likely to be clinically useful. A noninvasive measure of bladder pressure, allied to a free flow rate, would give a useful adjunct to the assessment of men with lower urinary tract symptoms.

Humans↗
PubMed2004

Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.

OBJECTIVE: To assess the efficacy and safety of duloxetine in women with stress urinary incontinence. DESIGN: Randomised double-blind, placebo-controlled clinical trial. SETTING: Fort-six centres in seven European countries and Canada. POPULATION: Four hundred and ninety-four women aged 24-83 years identified as having predominant symptoms of stress urinary incontinence using a clinical algorithm that was 100% predictive of urodynamic stress urinary incontinence in a subgroup of 34 women. METHODS: The case definition included a predominant symptom of stress urinary incontinence with a weekly incontinence episode frequency > or =7, the absence of predominant symptoms of urge incontinence, normal diurnal and nocturnal frequencies, a bladder capacity > or =400 mL and both a positive cough stress test and positive stress pad test. Subjects completed two urinary diaries prior to randomisation and three diaries during the active treatment phase of the study, each completed during the week prior to monthly visits. Subjects also completed quality of life questionnaires at each visit. Safety was assessed by the evaluation of treatment-emergent adverse events, discontinuation of treatment because of adverse events, serious adverse events, vital sign measurements, electrocardiograms (ECG) and clinical laboratory tests. INTERVENTION: After a two-week placebo lead-in, women received placebo or duloxetine 40 mg BD for 12 weeks. MAIN OUTCOME MEASURES: The percentage decrease in incontinence episode frequency and the change in the Incontinence Quality of Life (I-QOL) questionnaire total score were prespecified as co-primary outcome variables in the protocol. RESULTS: Incontinence episode frequency decreased significantly with duloxetine compared with placebo (median decrease of 50%vs 29%; P= 0.002) with comparable improvements in the more severely incontinent subgroup (those experiencing at least 14 incontinence episodes per week at baseline; 56%vs 27% decreases; P < 0.001). The primary analysis of I-QOL scores did not reveal a significant difference between treatment groups, due primarily to the carrying forward of low scores from patients who discontinued treatment very early due to duloxetine-associated adverse events. The increase in I-QOL scores was significantly greater for duloxetine than for placebo at each of the three postrandomisation visits after 4, 8, and 12 weeks of treatment. Discontinuation rates for adverse events were higher for duloxetine (22%vs 5%; P < 0.001) with nausea being the most common reason for discontinuation (5.3%). Nausea tended to be mild to moderate, not progressive, and transient. CONCLUSIONS: The findings support duloxetine as a potential treatment for women with stress urinary incontinence.

Adult↗
PubMed2004

The unstable detrusor.

The unstable detrusor (detrusor instability), a common condition in men and women, causes significant morbidity in sufferers and a great financial expense to health care providers. The condition is associated with symptoms of urinary frequency, urgency and urge incontinence. The embarrassing nature of these symptoms means patients are often reluctant to seek medical help and as a consequence there is under-reporting. Epidemiological studies are difficult to perform but appear to show that incidence increases with age and that the unstable detrusor is the commonest cause of male urinary incontinence. The aetiology is still much debated with reasoned arguments for both neurogenic and myogenic causes, though in truth, the likely explanation is multifactorial rather than a single underlying pathological process. The diagnosis can only be made on urodynamic testing. Before deciding on suitable treatment, the clinician must assess the disease severity and also its impact on patient quality of life. This is because perceived improvement in patient quality of life must outweigh any potential morbidity associated with treatment. Pharmacotherapy is based on blocking bladder muscarinic receptors. Unfortunately, no treatment is bladder specific and therefore most drug therapies have unwanted systemic anticholinergic side effects. Surgical treatment often involves a degree of bladder denervation to reduce bladder activity. This can consequently produce voiding difficulties which necessitate patients to self-catheterise on a longterm basis.

Female↗
PubMed2004

Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Overactive bladder (OAB) syndrome has been recognised by the International Continence Society as an important symptom syndrome that affects millions of people worldwide. Quality of life is affected in most people with OAB; however, the aetiology is unknown. Some researchers suggest that it is because of a damage to central inhibitory pathways or sensitisation of peripheral afferent terminals in the bladder, others suggest that it is a bladder muscle problem; the reality is probably a spectrum encompassing these two main explanations. Therefore, treatment is difficult and is aimed at alleviating symptoms (being those of urgency, with or without urge incontinence, usually with frequency and nocturia) rather than treating the cause. A thorough patient history and physical examination are required to establish a possible diagnosis. Frequency/volume charts form an important aid to the diagnosis. Once a presumptive diagnosis is made, conservative management forms the first line of treatment and includes lifestyle modifications, bladder training and pelvic floor exercises. If this fails, pharmacotherapy, in the form of anticholinergic drugs, is initiated. There are many antimuscarinic drugs, for example oxybutynin, tolterodine and trospium chloride. Each has a different specificity to bladder muscarinic receptors, thus producing different adverse effect profiles (e.g. dry mouth, blurred vision and constipation). Different individuals experience these adverse effects to different extents. New anticholinergic drugs, that have undergone phase III trials and are more specific to the muscarinic M3 human bladder receptor, are being introduced to the market in 2004 (e.g. solifenacin succinate and darifenacin). In addition to adverse effect profile, cost and improvement in quality of life are important factors in choosing treatment. Further research is being conducted on other types of drugs and different administration modalities, for example intravesical botulinum toxin A. Sacral nerve neuromodulation is emerging as a potential treatment, but if all treatments fail then surgery is the last resort.

Cost-Benefit Analysis↗
PubMed2003

Describing bladder storage function: overactive bladder syndrome and detrusor overactivity.

After a comprehensive review of terminology of lower urinary tract function/dysfunction, the International Continence Society (ICS) has recommended the use of the terms overactive bladder syndrome (OAB) and detrusor overactivity. Detrusor overactivity is defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase that may be spontaneous or provoked. Detrusor overactivity is subdivided into idiopathic detrusor overactivity and neurogenic detrusor overactivity. Because detrusor overactivity is a urodynamic diagnosis, it is essential to record symptoms and signs during urodynamic studies to correlate them with any involuntary contractions. The ICS 2002 report describes 2 types of detrusor overactivity: (1) phasic, which may or may not lead to urinary incontinence; and (2) terminal, which is a single involuntary detrusor contraction that often results in complete bladder emptying. OAB, as defined by ICS 2002, is a new term and is a symptomatic diagnosis. OAB is defined as urgency, with or without urge incontinence, and usually with frequency and nocturia. The ICS endorsement of the term OAB recognizes that patients with this symptom syndrome are almost always treated by nonsurgical means on an empirical basis, ie, without a urodynamic confirmation of the presumed diagnosis, detrusor overactivity. The ICS believes that these terms are more intuitive and will make it easier for patients and physicians alike to understand. It is hoped that general use of the new ICS definitions will facilitate effective communications between patients and their physicians concerning their urologic dysfunctions.

Humans↗
PubMed2003

The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder.

PURPOSE: The overactive bladder is a widespread medical condition with significant impact on quality of life. We review the existing evidence about the prevalence, impact and long-term followup of the overactive bladder. We also summarize the new International Continence Society terminology associated with the overactive bladder. MATERIALS AND METHODS: A MEDLINE search of all available literature regarding the epidemiology and long-term followup or outcome of the overactive bladder was performed. All articles and relevant resources cited in those articles were reviewed. RESULTS: The new International Continence Society terminology and definitions will allow greater consistency in future research. Two large, recently published surveys of the prevalence of overactive bladder give new insight into the widespread nature of the problem and its significant impact on quality of life. There is little good quality evidence currently available on the long-term outcome of overactive bladder. CONCLUSIONS: There is little published evidence regarding the natural history of overactive bladder. While recent studies have improved understanding the prevalence of the condition, we still know little about long-term outcome. The few published studies suggest that it is a chronic condition that persists urodynamically and symptomatically.

Humans↗
PubMed2003

Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury.

PURPOSE: We evaluated the efficacy and safety of tamsulosin in patients with neurogenic lower urinary tract dysfunction secondary to suprasacral spinal cord lesions in a 4-week randomized controlled trial (RCT) followed by a 1-year, open label, long-term study. MATERIALS AND METHODS: A total of 263 patients were randomized to 4-week double-blind therapy with placebo, or 0.4 or 0.8 mg tamsulosin once daily. Of these, 244 patients completed the RCT, 186 continued long-term tamsulosin therapy (0.4 or 0.8 mg once daily) and 134 completed 1-year treatment. The primary efficacy parameter was maximum urethral pressure (MUP). RESULTS: Although the mean decrease in MUP at 4 weeks in the RCT did not reach statistical significance over the placebo, it was more pronounced with 0.4 (-12.2 cm H2O or -10%) and 0.8 mg (-9.6 cm H2O or -9%) tamsulosin than placebo (-6.5 cm H2O or -3%). In the long-term study there was a statistically significant mean decrease in MUP (-18.0 cm H2O, p <0.001 or -15%) from baseline to end point. In the long-term study tamsulosin also decreased maximum urethral closure pressure, improved several cystometry parameters related to bladder storage and emptying, and increased to a statistically significantly degree, from baseline to end point, mean voided volume based on the micturition diary. There was statistically significant improvement for the International Prostate Symptom Score Quality of Life, as well as several questions about symptoms related to urinary leakage, and 1 question on bladder emptying and frequency, bother and severity of symptoms of autonomic dysreflexia. Finally, 71% of patients improved according to investigators (44% slightly and 27% much improved). Both doses were effective and well tolerated. CONCLUSIONS: Long-term tamsulosin treatment (0.4 and 0.8 mg once daily) seems to be effective and well tolerated in patients with neurogenic lower urinary tract dysfunction. The results suggest that it improves bladder storage and emptying, and decreases symptoms of autonomic dysreflexia.

Adolescent↗
PubMed2003

Including a 'no active intervention' arm in surgical trials is possible: evidence from the CLasP randomised trial.

OBJECTIVES: To examine the impact of including a 'no active intervention' arm (called 'conservative management') in a randomised controlled trial comparing treatments (including surgery) for men with lower urinary tract symptoms related to benign prostatic enlargement. METHODS: Outcomes 7.5 months after randomisation were acceptability of randomisation, overall acceptability of and satisfaction with conservative management, impact on quality of life, perceived need for further treatment and treatment failure (defined a priori). RESULTS: In total, 177 (out of 755) patients refused randomisation, including 31% who did not want surgery and 22% who wanted surgery. Most men randomised to conservative management were willing to undertake it as part of a trial but at the end of the trial they were divided between those who wanted to continue with it and those who expected surgery. At follow-up, 39% of conservative management patients requested surgery, and interference of symptoms with life and an unsuccessful outcome were more commonly reported in this arm. There were no appreciable differences between treatment groups in terms of treatment failures. CONCLUSIONS: Including a 'no active intervention' arm did not appear to have a detrimental effect on patient recruitment or the completion of this trial in the short-term; overall, conservative management was successfully completed by the majority of patients during the trial period, suggesting that researchers need not avoid including a no-intervention arm in surgical trials as long as they take care with its presentation.

Aged↗
PubMed2002

Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial.

OBJECTIVE: To examine the impact on sexual function of treatments for lower urinary tract symptoms in men. DESIGN: Multicentre pragmatic randomised controlled trial of standard surgery (transurethral resection of the prostate), non-contact laser therapy, and conservative management (no active intervention). SETTING: Three clinical centres in the United Kingdom. PARTICIPANTS: 340 men aged between 48 and 90 years with lower urinary tract symptoms related to benign prostatic enlargement. MAIN OUTCOME MEASURES: ICSsex questionnaire items concerned with erectile stiffness, ejaculatory volume, pain or discomfort on ejaculation, whether sex life was spoilt by urinary symptoms. RESULTS: Erectile and ejaculatory dysfunction were common (70%) and problematic at baseline and showed the expected trends with ageing. After treatment, reduced ejaculation was reported in all groups but was not significantly worse after standard surgery than after laser therapy. Erectile function was significantly improved after standard surgery; no significant difference was found between standard surgery and laser therapy (odds ratio 0.70, 95% confidence interval 0.36 to 1.38). Standard surgery was significantly better at relieving pain or discomfort on ejaculation than either conservative management (0.06, 0.007 to 0.49) or laser therapy (0.09, 0.01 to 0.73). CONCLUSIONS: Compared with laser therapy standard surgery for lower urinary tract symptoms has a beneficial effect on aspects of sexual function-particularly in improving erectile function and reducing reported pain or discomfort on ejaculation. Older men who need treatment and want to retain or improve sexual function may thus want to consider standard surgery rather than non-contact laser therapy.

Aged↗
PubMed2002

Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies.

This is the first report of the International Continence Society (ICS) on the development of comprehensive guidelines for Good Urodynamic Practice for the measurement, quality control, and documentation of urodynamic investigations in both clinical and research environments. This report focuses on the most common urodynamics examinations; uroflowmetry, pressure recording during filling cystometry, and combined pressure-flow studies. The basic aspects of good urodynamic practice are discussed and a strategy for urodynamic measurement, equipment set-up and configuration, signal testing, plausibility controls, pattern recognition, and artifact correction are proposed. The problems of data analysis are mentioned only when they are relevant in the judgment of data quality. In general, recommendations are made for one specific technique. This does not imply that this technique is the only one possible. Rather, it means that this technique is well-established, and gives good results when used with the suggested standards of good urodynamic practice.

Diagnostic Techniques, Urological↗